



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

March 3, 2026

Corporate Relationship Department  
BSE Ltd.  
**Mumbai 400 001**

Manager – Listing  
National Stock Exchange of India Ltd  
**Mumbai 400 051**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

**Sub:** Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information.

Thanking you,

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer

**NATCO Pharma Ltd**

Natco House  
Road No.2, Banjara Hills  
Hyderabad-500 034, India

**NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst®) in the U.S. market**

**Hyderabad, India, March 3<sup>rd</sup>, 2026:** NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") along with its partner Breckenridge Pharmaceutical, Inc announces launch of Pomalidomide Capsules, a generic version of Pomalyst® by Celgene in the U.S. market.

Pomalidomide Capsules, a thalidomide analogue, is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in 1mg, 2mg, 3mg, and 4mg strengths and is distributed primarily through specialty pharmacies and clinics.

Pomalidomide Capsules, 1mg, 2mg, 3mg and 4mg, had estimated sales of USD 3.2 billion in the U.S. for 12 months ending Sep'25 as per industry sales data. NATCO believes based on information made available by the U.S. Food and Drug Administration (FDA) that it has 180 days of shared exclusivity.

**Rajeev Nannapaneni, Vice Chairman and Chief Executive Office of NATCO Pharma Limited** said "We are pleased to launch Pomalidomide Capsules in the U.S., this further strengthens our oncology and specialty portfolio in the U.S. The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide. We look forward to bringing more such complex and specialty products to the market in the coming years."

"Access and affordability continue to be major challenges for patients who depend on specialty therapies," said **Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, Inc.** "Breckenridge's launch of Pomalidomide Capsules delivers a high-quality, affordable generic solution, supported by copay assistance for eligible patients to help reduce treatment delays and ensure continuity of care. This milestone underscores Breckenridge's ongoing commitment to expanding our specialty generics portfolio and improving access to affordable therapies for patients with complex conditions."

**\*Safe Harbor Statement**

*All brand names and trademarks are the property of their respective owners*

**About NATCO Pharma Limited**

NATCO Pharma Limited, (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at [www.natcopharma.com](http://www.natcopharma.com).



## NATCO Pharma Ltd

Natco House  
Road No.2, Banjara Hills  
Hyderabad-500 034, India

**For further information or queries please contact:**

Rajeev Menon – Manager, Investor Relations  
Email: [r.menon@natcopharma.co.in](mailto:r.menon@natcopharma.co.in)

Rajesh Chebiyam – EVP, Crop Health Sciences  
Email: [investors@natcopharma.co.in](mailto:investors@natcopharma.co.in)

Tel: 040-23547532 / Ext – 323

**Follow us on:**

X (formerly Twitter): [https://twitter.com/pharma\\_natco](https://twitter.com/pharma_natco)

LinkedIn: <https://www.linkedin.com/company/natcopharma>